4D Molecular Therapeutics, Inc. (FDMT)
| Market Cap | 606.40M |
| Revenue (ttm) | 88.24M |
| Net Income (ttm) | -160.90M |
| Shares Out | 52.28M |
| EPS (ttm) | -2.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,021,419 |
| Open | 11.49 |
| Previous Close | 11.52 |
| Day's Range | 10.85 - 12.04 |
| 52-Week Range | 3.68 - 12.34 |
| Beta | 2.76 |
| Analysts | Buy |
| Price Target | 28.22 (+143.28%) |
| Earnings Date | Aug 10, 2026 |
About FDMT
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company’s lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is... [Read more]
Financial Performance
In 2025, 4D Molecular Therapeutics's revenue was $85.21 million, an increase of 230194.59% compared to the previous year's $37,000. Losses were -$140.11 million, -12.90% less than in 2024.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for FDMT stock is "Buy." The 12-month stock price target is $28.22, which is an increase of 143.28% from the latest price.
News
4D Molecular Therapeutics Transcript: AGM 2026
The virtual meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved by stockholders. Voting results will be filed with the SEC, and no questions were raised during the Q&A session.
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
4D Molecular Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing its gene therapy platform with 4D-150 in late-stage trials for wet AMD and DME, targeting significant reductions in treatment burden and aiming for a paradigm shift in retinal care. Key data readouts and trial initiations are expected over the next 12 months.
4D Molecular Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
4D-150, a gene therapy for wet AMD and diabetic eye disease, aims to provide sustained anti-VEGF expression, reducing treatment burden and improving patient outcomes. Phase II data show strong efficacy and safety, with phase III results expected next year. The product is positioned for seamless integration into current practice and significant market impact.
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th...
4D Molecular Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Aiming to transform retinal disease treatment, the company is advancing pivotal global trials for wet AMD and DME, targeting broad adoption with a competitively priced, always-on gene therapy. Strong financials support progress toward commercialization, with key data readouts expected soon.
4D Molecular Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
4D-150 is advancing rapidly in phase III for wet AMD and DME, showing strong efficacy, safety, and potential for significant treatment burden reduction. Commercialization is planned internally for the U.S., with global partnerships considered, and manufacturing is on track. Cash runway extends into 2028.
4D Molecular price target lowered to $33 from $38 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on 4D Molecular (FDMT) to $33 from $38 and keeps a Buy rating on the shares. 4D Molecular Therapeutics reported Q1 results and…
4D Molecular files $400M mixed securities shelf
16:59 EDT 4D Molecular (FDMT) files $400M mixed securities shelf
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
EMERYVILLE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th...
4D Molecular Therapeutics Registration statement: Registration filing
4D Molecular Therapeutics filed a registration statement on May 7, 2026, providing details about a securities offering with the SEC.
4D Molecular Therapeutics Quarterly report: Q1 2026
4D Molecular Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
4D Molecular Therapeutics Earnings release: Q1 2026
4D Molecular Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
4D Molecular Therapeutics Slides: Corporate presentation
4D Molecular Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
4D Molecular Therapeutics Proxy statement: Proxy filing
4D Molecular Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
4D Molecular Therapeutics Proxy statement: Proxy filing
4D Molecular Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
4D Molecular price target lowered to $23 from $45 at Evercore ISI
Evercore ISI analyst Jonathan Miller lowered the firm’s price target on 4D Molecular (FDMT) to $23 from $45 and keeps an Outperform rating on the shares. The firm updated models…
4D Molecular assumed with a Buy at Jefferies
Jefferies analyst Faisal Khurshid assumed coverage of 4D Molecular (FDMT) with a Buy rating and a price target of $21, down from $40. The firm likes that 4D addresses the…
4D Molecular Therapeutics Annual report: Q4 2025
4D Molecular Therapeutics has published its Q4 2025 annual report on March 18, 2026.
4D Molecular Therapeutics Earnings release: Q4 2025
4D Molecular Therapeutics released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
4D Molecular Therapeutics Slides: Corporate presentation
4D Molecular Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 18, 2026.
4DMT to Participate in Upcoming Investor Meetings
EMERYVILLE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
4D Molecular Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
The company is advancing gene therapies for retinal diseases, with 4D-150 showing strong phase 2 efficacy and safety, and phase 3 trials fully enrolled or on track. Cash runway extends into 2028, and commercial plans include flexible pricing and independent US/EU launches.
4D Molecular Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Lead asset 4D-150 achieved rapid phase III enrollment, reflecting strong unmet need and physician enthusiasm. Commercialization strategies are tailored for U.S., EU, and Asia-Pacific, with broad label expectations and significant pricing flexibility. Cash runway extends into 2028.